Evolent Health in sale talks after receiving takeover interest, sources say
Corrects Aug 22 story to show that Elevance Health dropped out of the bidding process for Evolent at an earlier stage
By Milana Vinn and Anirban Sen
NEW YORK, Aug 22 (Reuters) -Evolent Health EVH.N is in talks with private equity firms and healthcare services providers for a potential sale, in a process that kicked off after it received takeover interest, people familiar with the matter said on Thursday.
Private equity firms TPG TPG.O, CD&R and KKR KKR.N are among the parties that have expressed interest in a deal for healthcare software provider Evolent, which has a market value of about $3.8 billion, the sources said. TPG was one of the early investors in Evolent.
Health insurer Elevance Health ELV.N also initially expressed an interest in bidding for Evolent, but a source familiar with the matter said on Monday that the company had dropped out of the process.
Evolent's shares jumped more than 18% on the news on Thursday. The shares, which have been trading in New York since the company's initial public offering in 2015, had declined about 14% from the start of the year until Wednesday's close.
Evolent, CD&R and Elevance did not immediately respond to requests for comment. KKR and TPG declined to comment.
Evolent, which is working with a financial adviser on the sale process that kicked off a few months ago, has received initial bids, the sources said. They added that a deal could be reached in the next few weeks.
The sources, who requested anonymity as the discussions are confidential, cautioned that a deal may not materialize.
Evolent, which has partnerships with healthcare providers and health insurers like Humana HUM.N, is a maker of software that enables them to migrate from fee-for-service reimbursement models towards value-based care models. In a value-based model, doctors and healthcare providers are reimbursed based on the quality of care they provide.
Evolent was founded in 2011 by UPMC Health Plan, which operates one of the largest U.S. provider-owned health plans, and The Advisory Board Company, which provides technology tools to hospitals and healthcare providers.
The company reported a 38% jump in revenue while its losses narrowed in its most recent quarter, but results fell short of market expectations as it was hurt by lower billing rates from its healthcare payer customers.
Activist investor Engaged Capital took a sizable stake in Evolent in 2020 and pushed the company to explore options to boost shareholder value. Engaged eventually entered into a settlement with the company that resulted in the creation of a strategy committee focused on "value creation initiatives."
Evolent has previously attracted takeover interest. In 2021, Bloomberg reported that Walgreens was weighing a deal for Evolent.
Reporting by Milana Vinn and Anirban Sen in New York; Editing by Paritosh Bansal and Nick Zieminski
Activos relacionados
Últimas noticias
Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.
Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.
Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.